We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -34.69 | -4.47% | 742.06 | 778.08 | 754.29 | 778.08 | 3,255,020 | 00:07:53 |
From May 2019 to May 2024
By Colin Kellaher
Eli Lilly & Co. and Boehringer Ingelheim on Tuesday said they plan to study whether their diabetes drug Jardiance can improve outcomes and prevent heart failure in adults with and without diabetes who have had a heart attack.
The two companies said they will provide funding for the study, which they will conduct in partnership with the Duke Clinical Research Institute, part of Duke University's School of Medicine.
Eli Lilly and Boehringer Ingelheim said the study will include about 3,300 adults across at least 16 countries who have had an acute myocardial infarction, more commonly known as a heart attack.
Indianapolis-based drug maker Eli Lilly and Boehringer Ingelheim, a family-owned pharmaceutical company based in Ingelheim, Germany, jointly market Jardiance as part of a 2011 alliance.
The new study is part of a broader clinical program exploring the impact of Jardiance on patients across the spectrum of cardio-renal-metabolic conditions, the companies said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 26, 2020 13:00 ET (17:00 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
